On March 1, 2018, the Launching Ceremony of the First Immunization Campaign for Japanese Encephalitis Vaccines was held in Indonesia. People in charge from the International Marketing Center of Sinopharm International and Chengdu Institute of Sinopharm CNBG participated in the ceremony upon the invitation of Indonesian Ministry of Health.
Nila F Moeloek, the Minister of Health of Indonesia, attended and addressed the ceremony. Representatives from the Indonesian Ministry of Health, relevant government agencies in Bali province and BioFarma, the agent of JE vaccine in Indonesia, were present. Minister Nila F Moeloek introduced the current status of JE epidemic and its immunization campaign in Indonesia. He expressed his sincere gratitude to Sinopharm International and Chengdu Institute, the supplier and the manufacturer of JE vaccineS, for their efficient supply. Afterwards, students from SMPN 1 Tabanan Middle School were vaccinated.
In recent years, Sinopharm International has actively explored the Indonesian vaccine market. They established the relationship with Indonesia’s largest vaccine manufacturer BioFarma in 2016 and started the registration of vaccines. In 2017, the first batch of JE vaccines of more than 1.1 million doses were exported to Indonesia which would be used for the immunization campaign among children aged 9 months to 15 years in Bali Province - the most affected area by encephalitis B - to contain the spread of the disease. According to the Indonesian Ministry of Health, Bali Province plans to add the JE vaccine into routine immunization starting from 2018; relevant public health departments are also conducting researches on encephalitis B in other areas outside Bali. It is expected that more areas will be included into the coverage of JE vaccine immunization campaign.
Sinopharm International will continue to provide JE vaccines of international standard to Indonesia and the whole Asian JE endemic area in cooperation with Chengdu Institute of Sinopharm CNBG and make positive efforts for disease control in related areas. (Reported by Sinopharm International)